A
Alice Mege
Publications - 4
Citations - 235
Alice Mege is an academic researcher. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 206 citations.
Papers
More filters
Journal ArticleDOI
Impact of Intensity-Modulated Radiotherapy on Health-Related Quality of Life for Head and Neck Cancer Patients: Matched-Pair Comparison with Conventional Radiotherapy
Pierre Graff,Michel Lapeyre,Emmanuel Desandes,Cécile Ortholan,René-Jean Bensadoun,M. Alfonsi,Philippe Maingon,Philippe Giraud,Jean Bourhis,Vincent Marchesi,Alice Mege,Didier Peiffert +11 more
TL;DR: The QOL assessment of head and neck cancer survivors demonstrated the benefit of IMRT, particularly in the areas of salivary dysfunction and oral discomfort.
Journal ArticleDOI
Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control
Laetitia Tournier-Rangeard,Michel Lapeyre,Pierre Graff-Caillaud,Alice Mege,Gilles Dolivet,Bruno Toussaint,Claire Charra-Brunaud,Sylvette Hoffstetter,Christian Marchal,Didier Peiffert +9 more
TL;DR: Local control of EMP in the HN seems to be improved when the dose to the CTV is > or = [DOSAGE ERROR CORRECTED] 45 Gy, and a minimum dose of 45 Gy should be recommended to theCTV.
Journal ArticleDOI
Genomics to select treatment for patients with metastatic breast cancer
Fabrice Andre,Thomas Filleron,Maud Kamal,F. Mosele,Monica Arnedos,Florence Dalenc,Marie Paule Sablin,Mario Campone,Hervé Bonnefoi,C. Lefeuvre-Plesse,William Jacot,Florence Coussy,Jean-Marc Ferrero,George Emile,Marie-Ange Mouret-Reynier,Jean-Christophe Thery,Nicolas Isambert,Alice Mege,P. Barthelemy,Benoit You,Nawale Hajjaji,Ludovic Lacroix,Etienne Rouleau,Alicia Tran-Dien,Sandrine Boyault,Valéry Attignon,Pierre Gestraud,Nicolas Servant,Christophe Le Tourneau,L. Larbi Chérif,Isabelle Soubeyran,Filippo Montemurro,Alain Morel,Amélie Lusque,Marta Jimenez,Alexandra Jacquet,Anthony Gonçalves,Thomas Bachelot,Ivan Bièche +38 more
TL;DR: Targeted therapies matched to genomics improved progression-free survival when genomic alterations were classified as level I/II (according to ESCAT), and genomics should be driven by target actionability in patients with metastatic breast cancer.
Journal ArticleDOI
[Improving healthcare organization of patients treated by anticancer oral therapy: What expectations?]
Léa Vazquez,J. Coussirou,J. Grenier,B. Billemont,Alice Mege,Gaëtan de Rauglaudre,Alma Stancu,Celeste David,A. Durand,Françoise Decrozals,Antoine Arnaud +10 more
TL;DR: In this article , the authors proposed an oral therapy unit (OTU) at the Avignon-Provence Cancer Institute (ICAP) for home-based anticancer oral therapies patients.